{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:24:12Z","timestamp":1785803052347,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40268-021-00351-6","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T04:02:35Z","timestamp":1624248155000},"page":"267-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Potential for the Repurposing of Adamantane Antivirals for COVID-19"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1503-5850","authenticated-orcid":false,"given":"Roger F.","family":"Butterworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"issue":"3","key":"351_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/BF01314742","volume":"66","author":"AG Bukrinskaya","year":"1980","unstructured":"Bukrinskaya AG, Vorkunova NK, Narmanbetova RA. Rimantadine hydrochloride blocks the second step of influenza virus uncoating. Arch Virol. 1980;66(3):275\u201382. https:\/\/doi.org\/10.1007\/BF01314742.","journal-title":"Arch Virol"},{"key":"351_CR2","doi-asserted-by":"publisher","unstructured":"Balgi AD, Wang J, Cheng DY, Ma C, Pfeifer TA, Shimizu Y, et al. Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay. PLoS One. 2013;8(2):e55271. https:\/\/doi.org\/10.1371\/journal.pone.0055271(Epub 2020 Mar 16).","DOI":"10.1371\/journal.pone.0055271"},{"issue":"4","key":"351_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1128\/aac.4.4.421","volume":"4","author":"A Mathur","year":"1973","unstructured":"Mathur A, Beare AS, Reed SE. In vitro antiviral activity and preliminary clinical trials of a new adamantane compound. Antimicrob Agents Chemother. 1973;4(4):421\u20136. https:\/\/doi.org\/10.1128\/aac.4.4.421.","journal-title":"Antimicrob Agents Chemother"},{"key":"351_CR4","doi-asserted-by":"publisher","unstructured":"Kolocouris A, Tzitzoglaki C, Johnson FB, Zell R, Wright AK, Cross TA, et al. Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A. J Med Chem. 2014;57(11):4629\u201339. https:\/\/doi.org\/10.1021\/jm500598u(Epub 2014 May 15).","DOI":"10.1021\/jm500598u"},{"issue":"3\u20134","key":"351_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/BF01310747","volume":"114","author":"HR Payne","year":"1990","unstructured":"Payne HR, Storz J, Henk WG. Initial events in bovine coronavirus infection: analysis through immunogold probes and lysosomotropic inhibitors. Arch Virol. 1990;114(3\u20134):175\u201389. https:\/\/doi.org\/10.1007\/BF01310747.","journal-title":"Arch Virol"},{"issue":"3","key":"351_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.chembiol.2005.01.006","volume":"12","author":"JA Tanner","year":"2005","unstructured":"Tanner JA, Zheng BJ, Zhou J, Watt RM, Jiang JQ, Wong KL, et al. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol. 2005;12(3):303\u201311. https:\/\/doi.org\/10.1016\/j.chembiol.2005.01.006.","journal-title":"Chem Biol"},{"issue":"6","key":"351_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/jmv.25752","volume":"92","author":"N Cimolai","year":"2020","unstructured":"Cimolai N. Potentially repurposing adamantanes for COVID-19. J Med Virol. 2020;92(6):531\u20132. https:\/\/doi.org\/10.1002\/jmv.25752(Epub 2020 Mar 16).","journal-title":"J Med Virol"},{"issue":"4","key":"351_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/v13040539","volume":"13","author":"K Fink","year":"2021","unstructured":"Fink K, Nitsche A, Neumann M, Grossegesse M, Eisele KH, Danysz W. Amantadine inhibits SARS-CoV-2 in vitro. Viruses. 2021;13(4):539. https:\/\/doi.org\/10.3390\/v13040539.","journal-title":"Viruses."},{"issue":"6","key":"351_CR9","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1021\/acsptsci.0c00172","volume":"3","author":"AM Baig","year":"2020","unstructured":"Baig AM, Khaleeq A, Syeda H. Docking prediction of amantadine in the receptor binding domain of spike protein of SARS-CoV-2. ACS Pharmacol Transl Sci. 2020;3(6):1430\u20133. https:\/\/doi.org\/10.1021\/acsptsci.0c00172.","journal-title":"ACS Pharmacol Transl Sci."},{"key":"351_CR10","doi-asserted-by":"publisher","unstructured":"Abreu GEA, Aguilar MEH, Covarrubias DH, Dur\u00e1n FR. Amantadine as a drug to mitigate the effects of COVID-19. Med Hypotheses. 2020;140:109755. https:\/\/doi.org\/10.1016\/j.mehy.2020.109755(Epub 2020 Apr 25).","DOI":"10.1016\/j.mehy.2020.109755"},{"issue":"11","key":"351_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.558557","volume":"27","author":"Z Li","year":"2020","unstructured":"Li Z, Yang L. Underlying mechanisms and candidate drugs for COVID-19 based on the connectivity map database. Front Genet. 2020;27(11): https:\/\/doi.org\/10.3389\/fgene.2020.558557.","journal-title":"Front Genet."},{"key":"351_CR12","doi-asserted-by":"publisher","unstructured":"Singh Tomar PP, Arkin IT. SARS-CoV-2 E protein is a potential ion channel that can be inhibited by gliclazide and memantine. BiochemBiophys Res Commun. 2020;30(1):10\u201314. https:\/\/doi.org\/10.1016\/j.bbrc.2020.05.206(Epub 2020 Jun 20).","DOI":"10.1016\/j.bbrc.2020.05.206"},{"key":"351_CR13","doi-asserted-by":"publisher","unstructured":"Mandala VS, McKay MJ, Shcherbakov AA, Dregni AJ, Kolocouris A, Hong M. Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers. Nat Struct Mol Biol. 2020;27(12):1202\u20138. https:\/\/doi.org\/10.1038\/s41594-020-00536-8(Epub 2020 Nov 11).","DOI":"10.1038\/s41594-020-00536-8"},{"key":"351_CR14","doi-asserted-by":"publisher","unstructured":"Surya W, Li Y, Torres J. Structural model of the SARS coronavirus E channel in LMPG micelles. Biochim Biophys Acta Biomembr. 2018;1860(6):1309\u201317. https:\/\/doi.org\/10.1016\/j.bbamem.2018.02.017(Epub 2018 Feb 21).","DOI":"10.1016\/j.bbamem.2018.02.017"},{"key":"351_CR15","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-121743\/v1","author":"MG Jeppesen","year":"2021","unstructured":"Jeppesen MG, Toft-Bertelsen TL, Kledal TN, Rosenkilde MM. Amantadin has potential for the treatment of COVID-19 because it targets known and novel ion channels encoded by SARS-CoV-2. Res Sq. 2021. https:\/\/doi.org\/10.21203\/rs.3.rs-121743\/v1.","journal-title":"Res Sq."},{"key":"351_CR16","doi-asserted-by":"publisher","unstructured":"Smieszek SP, Przychodzen BP, Polymeropoulos MH. Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment. Int J Antimicrob Agents. 2020;55(6):106004. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106004(Epub 2020 Apr 30).","DOI":"10.1016\/j.ijantimicag.2020.106004"},{"key":"351_CR17","doi-asserted-by":"publisher","unstructured":"Tzitzoglaki C, McGuire K, Lagarias P, Konstantinidi A, Hoffmann A, Fokina NA, et al. Chemical probes for blocking of influenza A M2 wild-type and S31N channels. ACS Chem Biol. 2020;15(9):2331\u20137. https:\/\/doi.org\/10.1021\/acschembio.0c00553(Epub 2020 Aug 27).","DOI":"10.1021\/acschembio.0c00553"},{"issue":"1","key":"351_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-021-00558-8","volume":"6","author":"MM Zhao","year":"2021","unstructured":"Zhao MM, Yang WL, Yang FY, Zhang L, Huang WJ, Hou W, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Targ Ther. 2021;6(1):134. https:\/\/doi.org\/10.1038\/s41392-021-00558-8.","journal-title":"Signal Transduct Targ Ther."},{"key":"351_CR19","doi-asserted-by":"publisher","unstructured":"Li YC, Bai WZ, Hashikawa T. Response to commentary on \u201cThe neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients\u201d. J Med Virol. 2020;92(7):707\u20139. https:\/\/doi.org\/10.1002\/jmv.25824(Epub 2020 Apr 10).","DOI":"10.1002\/jmv.25824"},{"issue":"1","key":"351_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.13188\/2327-204X.S200005","volume":"8","author":"SR Brenner","year":"2020","unstructured":"Brenner SR, Butterworth RF. Repurposing of adamantanes with transmitter receptor antagonist properties for the prevention\/treatment of COVID-19. J Pharmaceu Pharmacol. 2020;8(1):4. https:\/\/doi.org\/10.13188\/2327-204X.S200005.","journal-title":"J Pharmaceu Pharmacol"},{"issue":"2","key":"351_CR21","doi-asserted-by":"publisher","first-page":"2001610","DOI":"10.1183\/13993003.01610-2020","volume":"56","author":"S Hasanagic","year":"2020","unstructured":"Hasanagic S, Serdarevic F. Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond. Eur Respir J. 2020;56(2):2001610. https:\/\/doi.org\/10.1183\/13993003.01610-2020.","journal-title":"Eur Respir J"},{"issue":"1","key":"351_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jmv.26179","volume":"93","author":"GE Aranda-Abreu","year":"2021","unstructured":"Aranda-Abreu GE, Aranda-Martinez JD, Araujo R. Use of amantadine in a patient with SARS-CoV-2. J Med Virol. 2021;93(1):110\u20131. https:\/\/doi.org\/10.1002\/jmv.26179.","journal-title":"J Med Virol"},{"issue":"1","key":"351_CR23","first-page":"7","volume":"7","author":"RF Butterworth","year":"2020","unstructured":"Butterworth RF. Amantadine for the treatment of Parkinson\u2019s disease and its associated dyskinesias. J Parkinsons Dis Alzheimer Dis. 2020;7(1):7.","journal-title":"J Parkinsons Dis Alzheimer Dis."},{"key":"351_CR24","doi-asserted-by":"publisher","unstructured":"Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020;42:102163. https:\/\/doi.org\/10.1016\/j.msard.2020.102163(Epub 2020 Apr 30).","DOI":"10.1016\/j.msard.2020.102163"},{"issue":"1","key":"351_CR25","first-page":"4","volume":"7","author":"RF Butterworth","year":"2020","unstructured":"Butterworth RF. Amantadine treatment for Parkinson\u2019s disease during COVID-19: bimodal action targeting viral replication and the NMDA receptor. J Parkinsons Dis Alzheimer Dis. 2020;7(1):4.","journal-title":"J Parkinsons Dis Alzheimer Dis."},{"key":"351_CR26","doi-asserted-by":"publisher","unstructured":"Park MH, Kwon DY. A retrospective review of memantine use and COVID-19-associated mortality from a national database. J Med Virol. 2021;93(1):168\u20139. https:\/\/doi.org\/10.1002\/jmv.26266(Epub 2020 Jul 14).","DOI":"10.1002\/jmv.26266"},{"issue":"1","key":"351_CR27","first-page":"1","volume":"3","author":"RF Butterworth","year":"2020","unstructured":"Butterworth RF. Amantadine for the treatment of traumatic brain injury and its associated cognitive and neurobehavioral complications. J Pharmacol Pharm Res. 2020;3(1):1\u20135.","journal-title":"J Pharmacol Pharm Res."},{"key":"351_CR28","doi-asserted-by":"publisher","unstructured":"Brison E, Jacomy H, Desforges M, Talbot PJ. Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus. J Virol. 2014;88(3):1548\u201363. https:\/\/doi.org\/10.1128\/jvi.02972-13(Epub 2013 Nov 13).","DOI":"10.1128\/jvi.02972-13"},{"issue":"18","key":"351_CR29","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1021\/jm00044a010","volume":"37","author":"N Kolocouris","year":"1994","unstructured":"Kolocouris N, Foscolos GB, Kolocouris A, Marakos P, Pouli N, Fytas G, et al. Synthesis and antiviral activity evaluation of some aminoadamantane derivatives. J Med Chem. 1994;37(18):2896\u2013902. https:\/\/doi.org\/10.1021\/jm00044a010.","journal-title":"J Med Chem"},{"key":"351_CR30","doi-asserted-by":"publisher","unstructured":"Kolocouris N, Kolocouris A, Foscolos GB, Fytas G, Neyts J, Padalko E, et al. Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2. J Med Chem. 1996;39(17):3307\u201318. https:\/\/doi.org\/10.1021\/jm950891z.","DOI":"10.1021\/jm950891z"},{"issue":"1","key":"351_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","volume":"31","author":"F Chen","year":"2004","unstructured":"Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69\u201375. https:\/\/doi.org\/10.1016\/j.jcv.2004.03.003.","journal-title":"J Clin Virol"},{"key":"351_CR32","doi-asserted-by":"publisher","unstructured":"Cort\u00e9s-Borra A, Aranda-Abreu GE. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. Pharmacol Rep. 2021;18:1\u20134. https:\/\/doi.org\/10.1007\/s43440-021-00231-5(Epub ahead of print).","DOI":"10.1007\/s43440-021-00231-5"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00351-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-021-00351-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00351-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T07:30:50Z","timestamp":1628839850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-021-00351-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1007\/s40268-021-00351-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]},"assertion":[{"value":"20 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Roger F. Butterworth has received ad hoc payments for consulting and speaker fees from Salix Pharmaceuticals (USA), Umecrine Pharmaceuticals (Sweden) and Merz Pharmaceuticals (Germany).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Roger F. Butterworth was the sole author of this article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}